지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.10
- 수록면
- 575 - 588 (14page)
- DOI
- 10.3350/cmh.2021.0155
이용수
초록· 키워드
오류제보하기
Background/Aims: Real-world studies assessing the effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) plus ribavirin (RBV) for Child-Pugh B/C hepatitis C virus (HCV)-related cirrhosis are limited.
Methods: We included 107 patients with Child-Pugh B/C HCV-related cirrhosis receiving SOF/VEL plus RBV for 12 weeks in Taiwan. The sustained virologic response rates at off-treatment week 12 (SVR12) for the evaluable population (EP), modified EP, and per-protocol population (PP) were assessed. The safety profiles were reported.
Results: The SVR12 rates in the EP, modified EP and PP were 89.7% (95% confidence interval [CI], 82.5?94.2%), 94.1% (95% CI, 87.8?97.3%), and 100% (95% CI, 96.2?100%). Number of patients who failed to achieve SVR12 were attributed to virologic failures. The SVR12 rates were comparable regardless of patient characteristics. One patient discontinued treatment because of adverse events (AEs). Twenty-four patients had serious AEs and six died, but none were related to SOF/VEL or RBV. Among the 96 patients achieving SVR12, 84.4% and 64.6% had improved Child-Pugh and model for endstage liver disease (MELD) scores. Multivariate analysis revealed that a baseline MELD score ≥15 was associated with an improved MELD score of ≥3 (odds ratio, 4.13; 95% CI, 1.16?14.71; P=0.02). Patients with chronic kidney disease (CKD) stage 1 had more significant estimated glomerular filtration rate declines than patients with CKD stage 2 (-0.42 mL/min/1.73 m2/month; P=0.01) or stage 3 (-0.56 mL/min/1.73 m2/month; P<0.001).
Conclusions: SOF/VEL plus RBV for 12 weeks is efficacious and well-tolerated for Child-Pugh B/C HCV-related cirrhosis.
목차
등록된 정보가 없습니다.
참고문헌 (42)
참고문헌 신청
Lauer GM / 2001 / Hepatitis C virus infection / N Engl J Med 345:41~52
Planas R / 2004 / Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients / J Hepatol 40:823~830
Zarrinpar A / 2013 / Liver transplantation : past, present and future / Nat Rev Gastroenterol Hepatol 10:434~440
Garcia-Retortillo M / 2002 / Hepatitis C virus kinetics during and immediately after liver transplantation / Hepatology 35:680~687
Forman LM / 2002 / The association between hepatitis C infection and survival after orthotopic liver transplantation / Gastroenterology 122:889~896
Planas R / 2004 / Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients / J Hepatol 40:823~830
Zarrinpar A / 2013 / Liver transplantation : past, present and future / Nat Rev Gastroenterol Hepatol 10:434~440
Garcia-Retortillo M / 2002 / Hepatitis C virus kinetics during and immediately after liver transplantation / Hepatology 35:680~687
Forman LM / 2002 / The association between hepatitis C infection and survival after orthotopic liver transplantation / Gastroenterology 122:889~896
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function
Clinical and Molecular Hepatology
2017 .01
-
Prognostic indicators and risk factors for the in-hospital mortality rate of patients with cirrhosis
International Journal of Gastrointestinal Intervention
2024 .07
-
Real-World Single-Center Experience with Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C Genotype 1 Patients
Gut and Liver
2017 .01
-
The impact of Model for End-Stage Liver Disease score on deceased donor liver transplant outcomes in low volume liver transplantation center: a retrospective and singlecenter study
Annals of Surgical Treatment and Research
2021 .12
-
Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis
Clinical and Molecular Hepatology
2022 .10
-
Mortality scoring systems for liver transplant recipients: before and after model for end-stage liver disease score
Anesthesia and Pain Medicine
2023 .01
-
High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients
Gut and Liver
2020 .01
-
Patients with Liver Cirrhosis
대한외과학회 학술대회 초록집
2021 .11
-
The Impact of Sarcopenia and Its Rate of Change on Prognostic Value of Liver Cirrhosi
Journal of Korean Medical Science
2018 .01
-
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety
Gut and Liver
2018 .01
-
Efficacy of liver resection for single large hepatocellular carcinoma in Child-Pugh A cirrhosis: Analysis of nationwide cancer registry database
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Changes in liver allocation policy (MELD score) in US
한국간담췌외과학회 학술대회지
2016 .04
-
Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
Gut and Liver
2016 .01
-
Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients
Clinical and Molecular Hepatology
2019 .01
-
Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis
Gut and Liver
2021 .01
-
Development and surveillance of hepatocellular carcinoma in patients with sustained virologic response after antiviral therapy for chronic hepatitis C
Clinical and Molecular Hepatology
2019 .01
-
Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose
Gut and Liver
2020 .01
-
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced
Gut and Liver
2017 .01
-
Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
Clinical and Molecular Hepatology
2020 .01
-
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
Clinical and Molecular Hepatology
2018 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0